Under one in 10 patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it releases its inaugural guidance on the drugs.
Given more than one billion people worldwide currently obese, it is urging increased and just availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be treated with thorough and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are significant hurdles to widespread availability to the treatments that can assist patients in reducing considerable weight, notes the organization.
Skinny Jab Supply Crisis
Even under the current best projected case, the production of GLP-1 therapies might only reach about 100 million people – under 10% of those who need them, according to the health organization.
The advice encourages governments and firms to increase access, by measures like voluntary licensing.
Exclusive production rights on a key compound – the core component of a leading brand – is set to lapse in several nations in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs mimick a body's own hormone to slow digestion, curb appetite and enhance the sense of being full so individuals consume fewer calories.
Individuals typically see weight reduction within a few weeks of starting on the weekly injections.
Research indicates people may regain a significant portion a year later of stopping the medication, when their typical hunger resume.
Being carrying excess weight raises your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
